Availability, cost, and prescription patterns of antihypertensive medications in primary health care in China: a nationwide cross-sectional survey

The Lancet

Volumn 390, Issue 10112, 2017, Pages 2559-2568

  Su, Meng ^a   Zhang, Qiuli ^a,b   Bai, Xueke ^a   Wu, Chaoqun ^a   Li, Yetong ^a   Mossialos, Elias ^c   Mensah, George A ^d   Masoudi, Frederick A ^e   Lu, Jiapeng ^a   Li, Xi ^a   Salas Vega, Sebastian ^c   Zhang, Anwen ^c   Lu, Yuan ^f   Nasir, Khurram ^g   Krumholz, Harlan M ^f   Jiang, Lixin ^a  

^a FUWAI HOSPITAL   (China)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c LONDON SCHOOL OF ECONOMICS   (United Kingdom)

^d NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^e UNIVERSITY OF COLORADO   (United States)

^f YALE UNIVERSITY   (United States)

^g MIAMI CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BENAZEPRIL; BETAXOLOL; BISOPROLOL; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; CILAZAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPROSARTAN; FELODIPINE; FOSINOPRIL; IMIDAPRIL; IRBESARTAN; LISINOPRIL; LOSARTAN; METOPROLOL; NIFEDIPINE; OLMESARTAN; PERINDOPRIL; PROPRANOLOL; QUINAPRIL; RAMIPRIL; TELMISARTAN; UNINDEXED DRUG; VALSARTAN;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; CHINA; CROSS-SECTIONAL STUDY; DRUG COST; FEMALE; HEALTH CARE ACCESS; HEALTH CARE PERSONNEL; HEALTH CENTER; HEALTH SURVEY; HUMAN; HYPERTENSION; MALE; MIDDLE AGED; PRESCRIPTION; PRIMARY HEALTH CARE; PRIORITY JOURNAL; RURAL AREA; URBAN AREA; AGED; CLINICAL PRACTICE; ECONOMICS; EPIDEMIOLOGY; STATISTICS AND NUMERICAL DATA; SUPPLY AND DISTRIBUTION;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; CHINA; CROSS-SECTIONAL STUDIES; DRUG COSTS; FEMALE; HUMANS; MALE; MIDDLE AGED; PRACTICE PATTERNS, PHYSICIANS'; PRIMARY HEALTH CARE;

EID: 85032579700     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(17)32476-5     Document Type: Article

References (43)

1. Lewington, S, Lacey, B, Clarke, R, et al. The burden of hypertension and associated risk for cardiovascular mortality in China. JAMA Intern Med 176 (2016), 524–532.
2. Wang, JG, Chinese hypertension guidelines. Pulse 3 (2015), 14–20.
3. Guan, X, Liang, H, Xue, Y, et al. An analysis of China's national essential medicines policy. J Public Health Policy 32 (2011), 305–319.
4. Feng, XL, Pang, M, Beard, J, Health system strengthening and hypertension awareness, treatment and control: data from the China Health and Retirement Longitudinal Study. Bull World Health Organ 92 (2014), 29–41.
5. Li, Y, Yang, L, Wang, L, et al. Burden of hypertension in China: a nationally representative survey of 174 621 adults. Int J Cardiol 227 (2017), 516–523.
6. Yang, L, Yan, J, Tang, X, et al. Prevalence, awareness, treatment, control and risk factors associated with hypertension among adults in southern China, 2013. PLoS One, 11, 2016, e0146181.
7. Li, D, Lv, J, Liu, F, et al. Hypertension burden and control in mainland China: analysis of nationwide data 2003–2012. Int J Cardiol 184 (2015), 637–644.
8. Lu, J, Lu, Y, Wang, X, et al. Prevalence, awareness, treatment, and control of hypertension in China: data from 1·7 million adults in a population-based screening study (China PEACE Million Persons Project. Lancet, 2017 published online Oct 25. http://dx.doi.org/10.1016/S0140-6736(17)32478-9.
9. Zhou, M, Wang, H, Zhu, J, et al. Cause-specific mortality for 240 causes in China during 1990–2013: a systematic subnational analysis for the Global Burden of Disease Study 2013. Lancet 387 (2016), 251–272.
10. Yang, G, Kong, L, Zhao, W, et al. Emergence of chronic non-communicable diseases in China. Lancet 372 (2008), 1697–1705.
11. Song, Y, Bian, Y, Petzold, M, et al. The impact of China's national essential medicine system on improving rational drug use in primary health care facilities: an empirical study in four provinces. BMC Health Serv Res, 14, 2014, 507.
12. Chen, Z, Launch of the health-care reform plan in China. Lancet 373 (2009), 1322–1324.
13. Liu, Q, Tian, X, Tian, J, et al. Evaluation of the effects of comprehensive reform on primary healthcare institutions in Anhui Province. BMC Health Serv Res, 14, 2014, 268.
14. Fang, Y, Wagner, AK, Yang, S, et al. Access to affordable medicines after health reform: evidence from two cross-sectional surveys in Shaanxi Province, western China. Lancet Glob Health 1 (2013), e227–e237.
15. Xi, X, Li, W, Li, J, et al. A survey of the availability, prices and affordability of essential medicines in Jiangsu Province, China. BMC Health Serv Res, 15, 2015, 345.
16. Lu, J, Xuan, S, Downing, NS, et al. Protocol for the China PEACE (Patient-centered Evaluative Assessment of Cardiac Events) million persons project pilot. BMJ Open, 6, 2016, e010200.
17. Su, M, Zhang, Q, Lu, J, et al. Protocol for a nationwide survey of primary health care in China: the China PEACE (Patient-centered Evaluative Assessment of Cardiac Events) MPP (million persons project) Primary Health Care Survey. BMJ Open, 7, 2017, e016195.
18. National Health and Family Planning Commission of the People's Republic of China. Number of health institutions by the end of April 2017. http://www.nhfpc.gov.cn/mohwsbwstjxxzx/s7967/201706/41573016be1b41719c8ca68dfab05e9d.shtml, 2017 (accessed Aug 20, 2017).
19. AMAP. https://restapi.amap.com/v3/geocode/geo?key=678c8e39ee3f8fc598c659b4ea84cc5c&address (accessed Sept 25, 2017).
20. Chinese Pharmacopoeia. Chinese Pharmacopoeia Commission; 2015 edn. http://eng.sfda.gov.cn/WS03/CL0757/122060.html (accessed Sept 22, 2017).
21. Instructions for users of Omron HEM-7430. http://www.healthcare.omron.co.jp/support/download/manual/pdf/HEM-7430_m.pdf (accessed Sept 22, 2017).
22. Liu, LS, Writing Group of Chinese Guidelines for the Management of Hypertension. 2010 Chinese guidelines for the management of hypertension. Zhonghua Xin Xue Guan Bing Za Zhi 39 (2011), 579–615.
23. James, PA, Oparil, S, Carter, BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 311 (2014), 507–520.
24. National Health and Family Planning Commission of China. National Essential Medicine List (2012 version). http://www.moh.gov.cn/wsb/pwsyw/201303/f01fcc9623284509953620abc2ab189e.shtml, 2013 (accessed May 30, 2017).
25. Revision Committee of the Chinese Guideline for Hypertension Management in Primary Care 2014. Chinese guideline for hypertension management in primary care 2014. Chin J Hypertens 23 (2015), 24–43.
26. National Bureau of Statistics of China. China Statistical Yearbook. http://www.stats.gov.cn/tjsj/ndsj/2016/indexch.htm, 2016 (accessed May 30, 2017).
27. Zheng, Z, Zhang, H, Yuan, X, et al. Comparing outcomes of coronary artery bypass grafting among large teaching and urban hospitals in China and the United States. Circ Cardiovasc Qual Outcomes, 10, 2017, e003327.
28. Wang, Y, Eldridge, N, Metersky, ML, et al. National trends in patient safety for four common conditions, 2005–2011. N Engl J Med 370 (2014), 341–351.
29. General Office of the Chinese State Council. Opinions on key tasks for deepening the health system reform 2016. http://www.nhfpc.gov.cn/tigs/s7846/201604/ede9ab7526aa4222a56c7b906ae334af.shtml, 2016 (accessed July 7, 2017).
30. Yang, L, Liu, C, Ferrier, JA, et al. Organizational barriers associated with the implementation of national essential medicines policy: a cross-sectional study of township hospitals in China. Soc Sci Med 145 (2015), 201–208.
31. Cheng, H, Prescribing pattern of antihypertensive drugs in a general hospital in central China. Int J Clin Pharm 33 (2011), 215–220.
32. Yang, H, Dib, HH, Zhu, M, et al. Prices, availability and affordability of essential medicines in rural areas of Hubei Province, China. Health Policy Plan 25 (2010), 219–229.
33. Ministry of Health of the People's Republic of China Treasury Department, State Administration of Traditional Chinese Medicine. Announcement on the National Basic Public Health Service Project in 2016. http://www.nhfpc.gov.cn/jws/s3577/201606/f29a4659c7f4455ca6f62f8d14eb4b02.shtml, 2016 (accessed July 7, 2017).
34. Hu, S, Essential medicine policy in China: pros and cons. J Med Econ 16 (2013), 289–294.
35. Mossialos, E, Ge, Y, Hu, J, et al. Pharmaceutical policy in China: challenges and opportunities for reform. http://www.euro.who.int/__data/assets/pdf_file/0020/320465/Pharmaceutical-policy-China-challenges-opportunities-reform.pdf?ua=1, 2016 (accessed Sept 22, 2017).
36. Mao, W, Chen, W, The zero mark-up policy for essential medicines at primary level facilities, 2013, World Health Organization, Geneva.
37. Yip, WC, Hsiao, WC, Chen, W, et al. Early appraisal of China's huge and complex health-care reforms. Lancet 379 (2012), 833–842.
38. Hogerzeil, HV, Liberman, J, Wirtz, VJ, et al. Promotion of access to essential medicines for non-communicable diseases: practical implications of the UN political declaration. Lancet 381 (2013), 680–689.
39. Porter, ME, A strategy for health care reform—toward a value-based system. N Engl J Med 361 (2009), 109–112.
40. Prasad, V, De Jesús, K, Mailankody, S, The high price of anticancer drugs: origins, implications, barriers, solutions. Nat Rev Clin Oncol 14 (2017), 381–390.
41. Jiang, L, Krumholz, HM, Li, X, et al. Achieving best outcomes for patients with cardiovascular disease in China by enhancing the quality of medical care and establishing a learning health-care system. Lancet 386 (2015), 1493–1505.
42. Ministry of Human Resources and Social Security of the People's Republic of China. Achievements of China's social insurance reform have attracted worldwide attention. http://www.mohrss.gov.cn/SYrlzyhshbzb/dongtaixinwen/buneiyaowen/201705/t20170525_271399.html, 2017 (accessed June 28, 2017).
43. Meng, Q, Xu, L, Zhang, Y, et al. Trends in access to health services and financial protection in China between 2003 and 2011: a cross-sectional study. Lancet 379 (2012), 805–814.